Source comparison
CJC-1295 Bone Health Protocol: Dosage Comparison
Low-dose maintenance 250–500 Once weekly Evening pre-sleep 15–25% Minimal. Insufficient to overcome age-related GH decline Underdosed for skeletal endpoint; suitable only for patients with intact GH secretion seeking mild support Standard twice-weekly 500–1000
This comparison does not assign a generated winner or score.
- Low-dose maintenance
- 250–500
- Once weekly
- Evening pre-sleep
- 15–25%
- Minimal. Insufficient to overcome age-related GH decline
- Underdosed for skeletal endpoint; suitable only for patients with intact GH secretion seeking mild support
- Standard twice-weekly
- 500–1000
- Twice weekly
- 30–50%
- Moderate. P1NP and osteocalcin increase 20–35%
- Optimal balance of efficacy and safety; matches bone remodeling kinetics without flattening GH pulsatility
- High-frequency
- 300–500
- Every other day
- 40–60%
- Paradoxically lower. GH receptor desensitization reduces IGF-1 per unit GH
- Excessive frequency blunts pulsatility; higher IGF-1 doesn't translate to superior bone outcomes
- Mistimed administration
- Morning/midday
- 25–40%
- Poor. IGF-1 elevation occurs during circadian trough for osteoblast receptor density
- Circadian misalignment wastes peptide effect; same serum levels produce 40% lower bone marker response